Testing effectiveness (Phase 2)Not Yet RecruitingNCT07793435What this trial is testingA Phase 1/2 Trial of ADI-212 in mCRPCWho this might be right forProstate Cancer Metastatic Adicet Therapeutics 12
Early research (Phase 1)Active Not RecruitingNCT05990751What this trial is testingMulti-modular Chimeric Antigen Receptor Targeting GD2 in NeuroblastomaWho this might be right forNeuroblastoma University College, London 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04718883What this trial is testingCD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell LymphomaWho this might be right forMantle Cell Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. 59
Testing effectiveness (Phase 2)UnknownNCT02715362What this trial is testingGPC3 Redirected Autologous T Cells for Advanced HCCWho this might be right forCarcinoma, Hepatocellular Shanghai GeneChem Co., Ltd. 30
Very early researchStudy completedNCT05907603What this trial is testingResearch Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)Who this might be right forNeoplasmsHematologic NeoplasmsHematologic Diseases Kai Lin Xu，MD 8
Early research (Phase 1)Active Not RecruitingNCT04003649What this trial is testingIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMWho this might be right forRecurrent GlioblastomaRefractory Glioblastoma City of Hope Medical Center 20
Early research (Phase 1)Looking for participantsNCT06786533What this trial is testingClinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AMLWho this might be right forRelapsed/Refractory Acute Myeloid Leukemia (R/R AML) Hemogenyx Pharmaceuticals LLC 18
Testing effectiveness (Phase 2)Looking for participantsNCT06150885What this trial is testingA Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid TumorsWho this might be right forSolid Tumor Ever Supreme Bio Technology Co., Ltd. 60
Not applicableEnrolling By InvitationNCT06701201What this trial is testingA Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell ProductWho this might be right forCancer Verismo Therapeutics 60
Very early researchEnrolling By InvitationNCT07240857What this trial is testingA Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate Cancer (CRPC) Zhejiang University 18
Early research (Phase 1)Looking for participantsNCT03240328What this trial is testingThe Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune FunctionWho this might be right forHIV/AIDS Guangzhou 8th People's Hospital 40
Very early researchUnknownNCT04184414What this trial is testingThe Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological MalignanciesWho this might be right forB Acute Lymphoblastic LeukemiaMantle Cell LymphomaFollicular Lymphoma PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)UnknownNCT04706936What this trial is testingNovel BCMA-targeted CAR-T Cell Therapy for Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Early research (Phase 1)Looking for participantsNCT05052528What this trial is testingFludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWho this might be right forRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma University of California, Davis 36
Testing effectiveness (Phase 2)WithdrawnNCT03252171What this trial is testingCAR-T Cell Immunotherapy for GD2 Positive Glioma PatientsWho this might be right forGD2 Positive GliomaCAR-T Cell Immunotherapy Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)Active Not RecruitingNCT06046040What this trial is testingTmPSMA-02 in mCRPCWho this might be right forMetastatic Castrate-Resistant Prostate Cancer (mCRPC) University of Pennsylvania 30
Large-scale testing (Phase 3)Looking for participantsNCT07441291What this trial is testingCD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTWho this might be right forB ALLAllogenetic Hematopoietic Stem Cell TransplantationMRD-positive Peking University People's Hospital 70
Early research (Phase 1)Active Not RecruitingNCT04049513What this trial is testingENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Who this might be right forLymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more Malaghan Institute of Medical Research 30
Testing effectiveness (Phase 2)UnknownNCT04337606What this trial is testingChidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorWho this might be right forNon Hodgkin Lymphoma Chinese PLA General Hospital 100
Early research (Phase 1)Looking for participantsNCT06153251What this trial is testingAssess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapsed and/or Refractory Multiple Myeloma Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187